PHASE IIIB SAFETY RESULTS FROM AN EXPANDED ACCESS PROTOCOL OF TALIMOGENE LAHERPAREPVEC FOR PATIENT WITH UNRESECTED, STAGE IIIB-IVM1C MELANOMA.

Thursday, July 26, 2018